Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence
Authors
Keywords
-
Journal
Nature Reviews Nephrology
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-11-21
DOI
10.1038/s41581-020-00367-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Innate immunity in diabetic kidney disease
- (2020) Sydney C. W. Tang et al. Nature Reviews Nephrology
- GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials
- (2020) Matthew P. Gilbert et al. Frontiers in Endocrinology
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sodium–Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease
- (2019) Radica Z. Alicic et al. DIABETES
- Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes
- (2019) Carolyn F. Deacon Frontiers in Endocrinology
- DPP-4 inhibition enhanced renal tubular and myocardial GLP-1 receptor expression decreased in CKD with myocardial infarction
- (2019) Seung Jung Kim et al. BMC Nephrology
- Mechanisms of GLP-1 receptor–independent renoprotective effects of the dipeptidyl peptidase type 4 inhibitor linagliptin in GLP-1 receptor knockout mice with 5/6 nephrectomy
- (2019) Ahmed A. Hasan et al. KIDNEY INTERNATIONAL
- Burden, access, and disparities in kidney disease
- (2019) Deidra C. Crews et al. KIDNEY INTERNATIONAL
- US Renal Data System 2018 Annual Data Report: Epidemiology of Kidney Disease in the United States
- (2019) Rajiv Saran et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Exenatide twice-daily does not affect renal function or albuminuria compared to titrated insulin glargine in patients with type 2 diabetes mellitus: a post-hoc analysis of a 52-week randomised trial
- (2019) M.H.A. Muskiet et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide attenuates pre-established atherosclerosis in apolipoprotein E deficient mice via regulation of immune cell phenotypes and pro-inflammatory mediators
- (2019) Robyn Bruen et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2019) Mansoor Husain et al. NEW ENGLAND JOURNAL OF MEDICINE
- WITHDRAWN: Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition
- (2019) Pouya Saeedi et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Glucagon-Like Peptide-1 Receptor Agonism Improves Nephrotoxic Serum Nephritis by Inhibiting T-Cell Proliferation
- (2019) Foteini Moschovaki Filippidou et al. AMERICAN JOURNAL OF PATHOLOGY
- Comparison of Kidney Transcriptomic Profiles of Early and Advanced Diabetic Nephropathy Reveals Potential New Mechanisms for Disease Progression
- (2019) Ying Fan et al. DIABETES
- Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial
- (2019) M. Angelyn Bethel et al. DIABETES CARE
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2019) Søren L Kristensen et al. Lancet Diabetes & Endocrinology
- Glucagon-like peptide-1 receptor expression and its functions are regulated by androgen
- (2019) Liying Zhu et al. BIOMEDICINE & PHARMACOTHERAPY
- 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2019) John B. Buse et al. DIABETES CARE
- GLP-1 secretion is regulated by IL-6 signalling: a randomised, placebo-controlled study
- (2019) Helga Ellingsgaard et al. DIABETOLOGIA
- Anti-inflammatory potentials of incretin-based therapies used in the management of diabetes
- (2019) Habib Yaribeygi et al. LIFE SCIENCES
- Inflammatory Mechanisms as New Biomarkers and Therapeutic Targets for Diabetic Kidney Disease
- (2018) Radica Z. Alicic et al. ADVANCES IN CHRONIC KIDNEY DISEASE
- Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
- (2018) Daniel J. Drucker Cell Metabolism
- Kidney Biomarkers and Decline in eGFR in Patients with Type 2 Diabetes
- (2018) Katherine G. Garlo et al. Clinical Journal of the American Society of Nephrology
- Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
- (2018) Katherine R Tuttle et al. Lancet Diabetes & Endocrinology
- Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk
- (2018) Benjamin M. Scirica et al. JAMA Cardiology
- Glucagon-Like Peptide-1 and its Cleavage Products are Renoprotective in Murine Diabetic Nephropathy
- (2018) Moellmann Julia et al. DIABETES
- Global trends in diabetes complications: a review of current evidence
- (2018) Jessica L. Harding et al. DIABETOLOGIA
- Co-storage and release of insulin-like peptide-5, glucagon-like peptide-1 and peptideYY from murine and human colonic enteroendocrine cells
- (2018) Lawrence J. Billing et al. Molecular Metabolism
- Preproglucagon Neurons in the Nucleus of the Solitary Tract Are the Main Source of Brain GLP-1, Mediate Stress-Induced Hypophagia, and Limit Unusually Large Intakes of Food
- (2018) Marie K. Holt et al. DIABETES
- GLP-1 Receptor in Pancreatic α-Cells Regulates Glucagon Secretion in a Glucose-Dependent Bidirectional Manner
- (2018) Yanqing Zhang et al. DIABETES
- Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk
- (2018) Julio Rosenstock et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial
- (2018) Marcel H A Muskiet et al. Lancet Diabetes & Endocrinology
- Inflammatory Ly6Chi monocytes and their conversion to M2 macrophages drive atherosclerosis regression
- (2017) Karishma Rahman et al. JOURNAL OF CLINICAL INVESTIGATION
- Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials
- (2017) Mohsen Mazidi et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Role of soluble and membrane-bound dipeptidyl peptidase-4 in diabetic nephropathy
- (2017) Ahmed A Hasan et al. JOURNAL OF MOLECULAR ENDOCRINOLOGY
- Tissue-Resident Lymphocytes in the Kidney
- (2017) Jan-Eric Turner et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy
- (2017) Adeera Levin et al. LANCET
- Enteroendocrine cells-sensory sentinels of the intestinal environment and orchestrators of mucosal immunity
- (2017) J J Worthington et al. Mucosal Immunology
- GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
- (2017) Marcel H. A. Muskiet et al. Nature Reviews Nephrology
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
- (2017) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Renal Outcomes in Type 2 Diabetes
- (2017) Johannes F.E. Mann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interleukin-6 predicts inflammation-induced increase of Glucagon-like peptide-1 in humans in response to cardiac surgery with association to parameters of glucose metabolism
- (2016) Corinna Lebherz et al. Cardiovascular Diabetology
- The Cardiovascular Biology of Glucagon-like Peptide-1
- (2016) Daniel J. Drucker Cell Metabolism
- Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system
- (2016) C. Klemann et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS
- (2016) Jan H. Cornel et al. DIABETES CARE
- Response to Comment on Crews et al. Role and Determinants of Adherence to Off-loading in Diabetic Foot Ulcer Healing: A Prospective Investigation. Diabetes Care 2016;39:1371–1377
- (2016) Ryan T. Crews et al. DIABETES CARE
- Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial
- (2016) Ofri Mosenzon et al. DIABETES CARE
- Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial
- (2016) Lennart Tonneijck et al. DIABETOLOGIA
- Effect of meal composition on postprandial glucagon-like peptide-1, insulin, glucagon, C-peptide, and glucose responses in overweight/obese subjects
- (2016) Meena Shah et al. EUROPEAN JOURNAL OF NUTRITION
- Peptide production and secretion in GLUTag, NCI-H716, and STC-1 cells: a comparison to native L-cells
- (2016) Rune Ehrenreich Kuhre et al. JOURNAL OF MOLECULAR ENDOCRINOLOGY
- Saxagliptin reduces renal tubulointerstitial inflammation, hypertrophy and fibrosis in diabetes
- (2016) Muralikrishna Gangadharan Komala et al. NEPHROLOGY
- Diabetes and Cause-Specific Mortality in Mexico City
- (2016) Jesus Alegre-Díaz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exenatide (a GLP-1 agonist) expresses anti-inflammatory properties in cultured human monocytes/macrophages in a protein kinase A and B/Akt manner
- (2016) Łukasz Bułdak et al. Pharmacological Reports
- Synthetic small molecule GLP-1 secretagogues prepared by means of a three-component indole annulation strategy
- (2016) Oleg G. Chepurny et al. Scientific Reports
- Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis
- (2016) Nathan R. Hill et al. PLoS One
- Cardiovascular events and all-cause mortality in a cohort of 57,946 patients with type 2 diabetes: associations with renal function and cardiovascular risk factors
- (2015) Lucia Cea Soriano et al. Cardiovascular Diabetology
- Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus
- (2015) Xiao-Wu Chen et al. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
- Exendin-4 attenuates renal tubular injury by decreasing oxidative stress and inflammation in streptozotocin-induced diabetic mice
- (2015) Serap Sancar-Bas et al. GROWTH FACTORS
- Worldwide access to treatment for end-stage kidney disease: a systematic review
- (2015) Thaminda Liyanage et al. LANCET
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
- (2015) Jennifer B. Green et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fructose stimulates GLP-1 but not GIP secretion in mice, rats, and humans
- (2014) Rune E. Kuhre et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Structure of Class B GPCRs: new horizons for drug discovery
- (2014) Andrea Bortolato et al. BRITISH JOURNAL OF PHARMACOLOGY
- Linagliptin-Mediated DPP-4 Inhibition Ameliorates Kidney Fibrosis in Streptozotocin-Induced Diabetic Mice by Inhibiting Endothelial-to-Mesenchymal Transition in a Therapeutic Regimen
- (2014) Keizo Kanasaki et al. DIABETES
- GLP-1 Secretion Is Increased by Inflammatory Stimuli in an IL-6-Dependent Manner, Leading to Hyperinsulinemia and Blood Glucose Lowering
- (2014) F. Kahles et al. DIABETES
- Simultaneous GLP-1 and Insulin Administration Acutely Enhances Their Vasodilatory, Antiinflammatory, and Antioxidant Action in Type 2 Diabetes
- (2014) Antonio Ceriello et al. DIABETES CARE
- GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody
- (2014) Charles Pyke et al. ENDOCRINOLOGY
- Acute effects of pistachio consumption on glucose and insulin, satiety hormones and endothelial function in the metabolic syndrome
- (2014) C W C Kendall et al. EUROPEAN JOURNAL OF CLINICAL NUTRITION
- Linagliptin Blocks Renal Damage in Type 1 Diabetic Rats by Suppressing Advanced Glycation End Products-Receptor Axis
- (2014) S. Nakashima et al. HORMONE AND METABOLIC RESEARCH
- Effects of the Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist Dulaglutide on Ambulatory Blood Pressure and Heart Rate in Patients With Type 2 Diabetes Mellitus
- (2014) Keith C. Ferdinand et al. HYPERTENSION
- Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy
- (2014) Yuliya Sharkovska et al. JOURNAL OF HYPERTENSION
- Serum amyloid A and inflammation in diabetic kidney disease and podocytes
- (2014) Robert J Anderberg et al. LABORATORY INVESTIGATION
- Sitagliptin Prevents Inflammation and Apoptotic Cell Death in the Kidney of Type 2 Diabetic Animals
- (2014) Catarina Marques et al. MEDIATORS OF INFLAMMATION
- Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes
- (2014) André J. Tremblay et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Changes in Diabetes-Related Complications in the United States, 1990–2010
- (2014) Edward W. Gregg et al. NEW ENGLAND JOURNAL OF MEDICINE
- GLP-1 Receptor Agonists for Type 2 Diabetes Mellitus: Recent Developments and Emerging Agents
- (2014) Jennifer M. Trujillo et al. PHARMACOTHERAPY
- Glucagon-like peptide-1 (GLP-1) and its split products GLP-1(9-37) and GLP-1(28-37) stabilize atherosclerotic lesions in apoe−/− mice
- (2013) Mathias Burgmaier et al. ATHEROSCLEROSIS
- Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes
- (2013) Ryo Kodera et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- DNA methylation of the glucagon-like peptide 1 receptor (GLP1R) in human pancreatic islets
- (2013) Elin Hall et al. BMC Medical Genetics
- Glucagon-Like Peptide 1 Reduces Endothelial Dysfunction, Inflammation, and Oxidative Stress Induced by Both Hyperglycemia and Hypoglycemia in Type 1 Diabetes
- (2013) A. Ceriello et al. DIABETES CARE
- Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus
- (2013) Andrew E. Hogan et al. DIABETOLOGIA
- Glucagon-Like Peptide-1 (GLP-1): Effect on Kidney Hemodynamics and Renin-Angiotensin-Aldosterone System in Healthy Men
- (2013) Jeppe Skov et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Exendin-4 ameliorates renal ischemia-reperfusion injury in the rat
- (2013) Hua Yang et al. JOURNAL OF SURGICAL RESEARCH
- Protection of Glucagon-Like Peptide-1 in Cisplatin-Induced Renal Injury Elucidates Gut-Kidney Connection
- (2013) D. Katagiri et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Kidney Disease and Increased Mortality Risk in Type 2 Diabetes
- (2013) M. Afkarian et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Exendin-4 and sitagliptin protect kidney from ischemia-reperfusion injury through suppressing oxidative stress and inflammatory reaction
- (2013) Yen-Ta Chen et al. Journal of Translational Medicine
- The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential
- (2013) Hiroki Fujita et al. KIDNEY INTERNATIONAL
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
- (2013) William B. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-inflammatory effects of exendin-4, a glucagon-like peptide-1 analog, on human peripheral lymphocytes in patients with type 2 diabetes
- (2013) Lan He et al. Journal of Diabetes Investigation
- DPP-4 Inhibitors as Therapeutic Modulators of Immune Cell Function and Associated Cardiovascular and Renal Insulin Resistance in Obesity and Diabetes
- (2013) Annayya Aroor et al. CardioRenal Medicine
- KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update
- (2012) AMERICAN JOURNAL OF KIDNEY DISEASES
- Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation
- (2012) Daisuke Shiraishi et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Opportunities for functional selectivity in GPCR antibodies
- (2012) David R. Webb et al. BIOCHEMICAL PHARMACOLOGY
- Risks of Subsequent Hospitalization and Death in Patients with Kidney Disease
- (2012) K. B. Daratha et al. Clinical Journal of the American Society of Nephrology
- Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment
- (2012) M. S. Fineman et al. DIABETES OBESITY & METABOLISM
- The Glucagon-Like Peptide-1 Receptor—or Not?
- (2012) Charles Pyke et al. ENDOCRINOLOGY
- Chronic DPP-IV inhibition with PKF-275-055 attenuates inflammation and improves gene expressions responsible for insulin secretion in streptozotocin induced diabetic rats
- (2012) Atul Sureshrao Akarte et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Dipeptidyl Peptidase IV Regulates Proliferation of Preglomerular Vascular Smooth Muscle and Mesangial Cells
- (2012) Edwin K. Jackson et al. HYPERTENSION
- GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases
- (2012) Hari Hendarto et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
- (2012) Juris J. Meier Nature Reviews Endocrinology
- The gut endocrine system as a coordinator of postprandial nutrient homoeostasis
- (2012) Fiona M. Gribble PROCEEDINGS OF THE NUTRITION SOCIETY
- The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes
- (2011) Ho-Sang Moon et al. ARCHIVES OF PHARMACAL RESEARCH
- Rapid Tachyphylaxis of the Glucagon-Like Peptide 1-Induced Deceleration of Gastric Emptying in Humans
- (2011) M. A. Nauck et al. DIABETES
- Short-Chain Fatty Acids Stimulate Glucagon-Like Peptide-1 Secretion via the G-Protein-Coupled Receptor FFAR2
- (2011) G. Tolhurst et al. DIABETES
- Effect of Exenatide on Inflammatory and Oxidative Stress Markers in Patients with Type 2 Diabetes Mellitus
- (2011) Jin-dan Wu et al. Diabetes Technology & Therapeutics
- Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes
- (2011) R. Kodera et al. DIABETOLOGIA
- Exenatide Exerts a Potent Antiinflammatory Effect
- (2011) Ajay Chaudhuri et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Glucagon-like peptide–1 suppresses advanced glycation end product–induced monocyte chemoattractant protein–1 expression in mesangial cells by reducing advanced glycation end product receptor level
- (2011) Yuji Ishibashi et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Incretin-Based Therapies for Type 2 Diabetes Mellitus: Properties, Functions, and Clinical Implications
- (2010) Michael A. Nauck AMERICAN JOURNAL OF MEDICINE
- Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4
- (2010) M. Arakawa et al. DIABETES
- Exenatide Affects Circulating Cardiovascular Risk Biomarkers Independently of Changes in Body Composition
- (2010) M. C. Bunck et al. DIABETES CARE
- Pharmacokinetics of dipeptidylpeptidase-4 inhibitors
- (2010) A. J. Scheen DIABETES OBESITY & METABOLISM
- Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells
- (2010) I. Hadjiyanni et al. DIABETOLOGIA
- Reversal of New-Onset Diabetes through Modulating Inflammation and Stimulating β-Cell Replication in Nonobese Diabetic Mice by a Dipeptidyl Peptidase IV Inhibitor
- (2010) Lei Tian et al. ENDOCRINOLOGY
- Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin – diabetes control and potential adverse events
- (2009) Bo Ahrén BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
- Phenotyping of congenic dipeptidyl peptidase 4 (DP4) deficient Dark Agouti (DA) rats suggests involvement of DP4 in neuro-, endocrine, and immune functions
- (2009) Nadine Frerker et al. CLINICAL CHEMISTRY AND LABORATORY MEDICINE
- Dipeptidyl Peptidase-4 (CD26): Knowing the Function before Inhibiting the Enzyme
- (2009) E. Matteucci et al. CURRENT MEDICINAL CHEMISTRY
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
- (2009) John B Buse et al. LANCET
- How reliable are G-protein-coupled receptor antibodies?
- (2009) Martin C. Michel et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- Glucose Sensing in L Cells: A Primary Cell Study
- (2008) Frank Reimann et al. Cell Metabolism
- Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study
- (2008) Ralph A. DeFronzo et al. CURRENT MEDICAL RESEARCH AND OPINION
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
- (2008) Daniel J Drucker et al. LANCET
- Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function
- (2008) Kei Ohnuma et al. TRENDS IN IMMUNOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started